Dr. Lane is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
450 Brookline Ave
Boston, MA 02215Phone+1 617-632-3000- Is this information wrong?
Education & Training
Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 2008 - 2012- Brigham and Women's HospitalResidency, Internal Medicine, 2006 - 2008
Washington University in St. Louis School of MedicineClass of 2006
Certifications & Licensure
MA State Medical License 2008 - 2025- American Board of Internal Medicine Hematology
Clinical Trials
- SL-401 in Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm or Acute Myeloid Leukemia Start of enrollment: 2014 Sep 01
- SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Start of enrollment: 2017 Jun 26
- Study of Venetoclax, a BCL2 Antagonist, for Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Start of enrollment: 2018 Aug 23
Publications & Presentations
PubMed
- Organ Involvement in Adults with BPDCN is Associated with Sun Exposure History, TET2 and RAS Mutations, and Survival.Julia H Keating, Christopher J Fay, Donna S Neuberg, Nicole R LeBoeuf, Shai Shimony, Marlise R Luskin, Andrew A Lane> ;Blood Advances. 2024 Apr 11
- 1 citationsPivekimab sunirine (IMGN632), a novel CD123-targeting antibody-drug conjugate, in relapsed or refractory acute myeloid leukaemia: a phase 1/2 study.Naval G Daver, Pau Montesinos, Daniel J DeAngelo, Eunice S Wang, Nikolaos Papadantonakis, Elisabetta Todisco, Kendra L Sweet, Naveen Pemmaraju, Andrew A Lane, Laura To...> ;The Lancet. Oncology. 2024 Mar 1
- Treatment of patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN): focus on the use of tagraxofusp and clinical considerations.Rizzieri, D., Pemmaraju, N., Madanat, Y., Fazal, S., Rampal, R., Mannis, G., Wang, E., Foran, J., Lane, A., Fazal, S.> ;Leukemia & Lymphoma. 2024 Feb 23
- Join now to see all
Abstracts/Posters
- Clinical Profile of IMGN632, a Novel CD123-Targeting Antibody-Drug Conjugate (ADC), in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) or Blastic ...Andrew A. Lane, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- A Phase I Study of IMGN632, a Novel CD123-Targeting Antibody-Drug Conjugate, in Patients with Relapsed/Refractory Acute Myeloid Leukemia, Blastic Plasmacytoid Dendriti...Andrew A. Lane, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Efficacy Proof of Concept for Allogeneic CD123 Targeting CAR T-Cells Against Primary Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): Efficient Control of Tumor P...Andrew A. Lane, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Join now to see all
Press Mentions
Stemline Therapeutics Announces That Pivotal Trial of SL-401 in Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Meets Primary EndpointOctober 31st, 2017
Link Between down Syndrome, Leukemia UncoveredApril 20th, 2014
Exposure to Ultraviolet Radiation May Propel Transformation of BPDCN Cells to Leukemia in the SkinJune 14th, 2023- Join now to see all
Hospital Affiliations
Dana-Farber Cancer InstituteBoston, Massachusetts
Brigham and Women's HospitalBoston, Massachusetts
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
